KPIs & Operating Metrics(New)
Growth Metrics

Amgen (AMGN) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Amgen (AMGN) over the last 17 years, with Q4 2025 value amounting to $90.6 billion.

  • Amgen's Liabilities and Shareholders Equity fell 136.43% to $90.6 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $358.0 billion, marking a year-over-year decrease of 235.07%. This contributed to the annual value of $90.6 billion for FY2025, which is 136.43% down from last year.
  • According to the latest figures from Q4 2025, Amgen's Liabilities and Shareholders Equity is $90.6 billion, which was down 136.43% from $90.1 billion recorded in Q3 2025.
  • In the past 5 years, Amgen's Liabilities and Shareholders Equity ranged from a high of $97.2 billion in Q4 2023 and a low of $59.2 billion during Q1 2022
  • Moreover, its 5-year median value for Liabilities and Shareholders Equity was $89.0 billion (2023), whereas its average is $79.4 billion.
  • Per our database at Business Quant, Amgen's Liabilities and Shareholders Equity tumbled by 805.71% in 2021 and then soared by 5223.97% in 2023.
  • Over the past 5 years, Amgen's Liabilities and Shareholders Equity (Quarter) stood at $61.2 billion in 2021, then rose by 6.47% to $65.1 billion in 2022, then soared by 49.19% to $97.2 billion in 2023, then dropped by 5.47% to $91.8 billion in 2024, then dropped by 1.36% to $90.6 billion in 2025.
  • Its Liabilities and Shareholders Equity stands at $90.6 billion for Q4 2025, versus $90.1 billion for Q3 2025 and $87.9 billion for Q2 2025.